|
Name |
sphaeropsidin C
|
Molecular Formula | C20H28O4 | |
IUPAC Name* |
(4aR,4bR,7R,10aS)-7-ethenyl-4b-hydroxy-1,1,7-trimethyl-9-oxo-3,4,5,6,10,10a-hexahydro-2H-phenanthrene-4a-carboxylic acid
|
|
SMILES |
C[C@@]1(CC[C@]2(C(=C1)C(=O)C[C@@H]3[C@@]2(CCCC3(C)C)C(=O)O)O)C=C
|
|
InChI |
InChI=1S/C20H28O4/c1-5-18(4)9-10-20(24)13(12-18)14(21)11-15-17(2,3)7-6-8-19(15,20)16(22)23/h5,12,15,24H,1,6-11H2,2-4H3,(H,22,23)/t15-,18-,19-,20+/m0/s1
|
|
InChIKey |
VIDNIVWPSMVGJV-MVJPYGJCSA-N
|
|
Synonyms |
sphaeropsidin C; CHEBI:69495; MLS003373235; CHEMBL1934132; SMR002047992; Q27137834; (4aR,4bR,7R,10aS)-7-ethenyl-4b-hydroxy-1,1,7-trimethyl-9-oxo-3,4,5,6,10,10a-hexahydro-2H-phenanthrene-4a-carboxylic acid
|
|
CAS | NA | |
PubChem CID | 10544575 | |
ChEMBL ID | CHEMBL1934132 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 332.4 | ALogp: | 3.7 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 74.6 | Aromatic Rings: | 3 |
Heavy Atoms: | 24 | QED Weighted: | 0.742 |
Caco-2 Permeability: | -5.156 | MDCK Permeability: | 0.00001960 |
Pgp-inhibitor: | 0.03 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.03 | 20% Bioavailability (F20%): | 0.006 |
30% Bioavailability (F30%): | 0.006 |
Blood-Brain-Barrier Penetration (BBB): | 0.918 | Plasma Protein Binding (PPB): | 85.00% |
Volume Distribution (VD): | 0.439 | Fu: | 15.21% |
CYP1A2-inhibitor: | 0.009 | CYP1A2-substrate: | 0.555 |
CYP2C19-inhibitor: | 0.036 | CYP2C19-substrate: | 0.638 |
CYP2C9-inhibitor: | 0.157 | CYP2C9-substrate: | 0.499 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.105 |
CYP3A4-inhibitor: | 0.347 | CYP3A4-substrate: | 0.414 |
Clearance (CL): | 1.007 | Half-life (T1/2): | 0.502 |
hERG Blockers: | 0.024 | Human Hepatotoxicity (H-HT): | 0.632 |
Drug-inuced Liver Injury (DILI): | 0.028 | AMES Toxicity: | 0.109 |
Rat Oral Acute Toxicity: | 0.08 | Maximum Recommended Daily Dose: | 0.895 |
Skin Sensitization: | 0.602 | Carcinogencity: | 0.599 |
Eye Corrosion: | 0.734 | Eye Irritation: | 0.885 |
Respiratory Toxicity: | 0.964 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002830 | 0.600 | D04GJN | 0.282 | ||||
ENC002731 | 0.541 | D01CKY | 0.279 | ||||
ENC002831 | 0.530 | D0Q6NZ | 0.275 | ||||
ENC002906 | 0.433 | D0I2SD | 0.269 | ||||
ENC001070 | 0.417 | D0L2LS | 0.265 | ||||
ENC001409 | 0.415 | D0Z1XD | 0.263 | ||||
ENC002923 | 0.388 | D0R7JT | 0.257 | ||||
ENC002083 | 0.380 | D06AEO | 0.250 | ||||
ENC002266 | 0.375 | D0KR5B | 0.250 | ||||
ENC002833 | 0.374 | D0IX6I | 0.250 |